563 related articles for article (PubMed ID: 30629157)
1. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
[TBL] [Abstract][Full Text] [Related]
3. Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model.
Helmink MAG; Hageman SHJ; Eliasson B; Sattar N; Visseren FLJ; Dorresteijn JAN; Harris K; Peters SAE; Woodward M; Szentkúti P; Højlund K; Henriksen JE; Sørensen HT; Serné EH; van Sloten TT; Thomsen RW; Westerink J
Diabetes Obes Metab; 2024 Jun; 26(6):2229-2238. PubMed ID: 38456579
[TBL] [Abstract][Full Text] [Related]
4. Development of a cardiovascular diseases risk prediction model and tools for Chinese patients with type 2 diabetes mellitus: A population-based retrospective cohort study.
Wan EYF; Fong DYT; Fung CSC; Yu EYT; Chin WY; Chan AKC; Lam CLK
Diabetes Obes Metab; 2018 Feb; 20(2):309-318. PubMed ID: 28722290
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Margolis KL; O'Connor PJ; Morgan TM; Buse JB; Cohen RM; Cushman WC; Cutler JA; Evans GW; Gerstein HC; Grimm RH; Lipkin EW; Narayan KM; Riddle MC; Sood A; Goff DC
Diabetes Care; 2014 Jun; 37(6):1721-8. PubMed ID: 24595629
[TBL] [Abstract][Full Text] [Related]
6. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
de Vries TI; Eikelboom JW; Bosch J; Westerink J; Dorresteijn JAN; Alings M; Dyal L; Berkowitz SD; van der Graaf Y; Fox KAA; Visseren FLJ
Eur Heart J; 2019 Dec; 40(46):3771-3778a. PubMed ID: 31504399
[TBL] [Abstract][Full Text] [Related]
7. Estimating individual lifetime risk of incident cardiovascular events in adults with Type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2).
Østergaard HB; Hageman SHJ; Read SH; Taylor O; Pennells L; Kaptoge S; Petitjean C; Xu Z; Shi F; McEvoy JW; Herrington W; Visseren FLJ; Wood A; Eliasson B; Sattar N; Wild S; Di Angelantonio E; Dorresteijn JAN
Eur J Prev Cardiol; 2023 Jan; 30(1):61-69. PubMed ID: 36208182
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study.
Østergaard HB; Humphreys V; Hengeveld EM; Honoré JB; Mach F; Visseren FLJ; Westerink J; Yadav G; Mosenzon O;
Diabetes Obes Metab; 2023 Feb; 25(2):435-443. PubMed ID: 36199242
[TBL] [Abstract][Full Text] [Related]
9. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
10. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people.
Jaspers NEM; Blaha MJ; Matsushita K; van der Schouw YT; Wareham NJ; Khaw KT; Geisel MH; Lehmann N; Erbel R; Jöckel KH; van der Graaf Y; Verschuren WMM; Boer JMA; Nambi V; Visseren FLJ; Dorresteijn JAN
Eur Heart J; 2020 Mar; 41(11):1190-1199. PubMed ID: 31102402
[TBL] [Abstract][Full Text] [Related]
11. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
Pagidipati NJ; Navar AM; Pieper KS; Green JB; Bethel MA; Armstrong PW; Josse RG; McGuire DK; Lokhnygina Y; Cornel JH; Halvorsen S; Strandberg TE; Delibasi T; Holman RR; Peterson ED;
Circulation; 2017 Sep; 136(13):1193-1203. PubMed ID: 28626088
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular disease morbidity and mortality in patients with type 1 diabetes mellitus : management strategies.
Soedamah-Muthu SS; Stehouwer CD
Treat Endocrinol; 2005; 4(2):75-86. PubMed ID: 15783245
[TBL] [Abstract][Full Text] [Related]
13. Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study.
Ong G; Davis TM; Davis WA
Diabetes Care; 2010 Feb; 33(2):317-21. PubMed ID: 19918016
[TBL] [Abstract][Full Text] [Related]
14. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
[TBL] [Abstract][Full Text] [Related]
15. Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.
Westerink J; Matthiessen KS; Nuhoho S; Fainberg U; Lyng Wolden M; Østergaard HB; Visseren F; Sattar N
Diabetes Care; 2022 May; 45(5):1211-1218. PubMed ID: 35263432
[TBL] [Abstract][Full Text] [Related]
16. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
van der Leeuw J; Visseren FL; Woodward M; Zoungas S; Kengne AP; van der Graaf Y; Glasziou P; Hamet P; MacMahon S; Poulter N; Grobbee DE; Chalmers J
Hypertension; 2015 Jan; 65(1):115-21. PubMed ID: 25312436
[TBL] [Abstract][Full Text] [Related]
17. Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease?
Selak V; Jackson R; Poppe K; Kerr A; Wells S
N Z Med J; 2018 Oct; 131(1484):19-25. PubMed ID: 30359352
[TBL] [Abstract][Full Text] [Related]
18. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus.
Huang ES; Meigs JB; Singer DE
Am J Med; 2001 Dec; 111(8):633-42. PubMed ID: 11755507
[TBL] [Abstract][Full Text] [Related]
19. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
[TBL] [Abstract][Full Text] [Related]
20. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
Valentine N; Van de Laar FA; van Driel ML
Cochrane Database Syst Rev; 2012 Nov; 11():CD005449. PubMed ID: 23152231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
